Case Study

Meeting Enrollment Early With 100% Retention in a Phase 2 Migraine Study

At Tekton’s Yukon, Oklahoma site (now Oklahoma City), the team delivered a Phase 2 migraine treatment study with rapid startup, early enrollment completion, full participant retention, and near-perfect diary compliance. Participant education and proactive follow-up supported adherence throughout the study.

  • Enrollment goal met ahead of schedule
  • First participant visit within 48 hours of activation
  • 1.5 days from regulatory receipt to submission
  • 100% retention and near-perfect diary compliance

Talk to Tekton

Episodic Migraine

About This Study

CLIENT
Biotech
TRIAL
Phase 2 migraine treatment study
SITE LOCATION
Yukon, OK (now Oklahoma City)

Partner With Tekton

Join leading Sponsors and CROs that trust Tekton's sites to support their most important clinical trials.

Complete the form on this page or email to discuss your protocol, target population, timelines, and site needs.

Submit Your Information